The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.S. Lawmaker Launches Investigation into Pharma Drug Pricing

U.S. Lawmaker Launches Investigation into Pharma Drug Pricing

January 15, 2019 • By Yasmeen Abutaleb

  • Tweet
  • Email
Print-Friendly Version / Save PDF

WASHINGTON (Reuters)—A top U.S. lawmaker has launched an investigation into pharmaceutical industry pricing practices, less than a week after he and fellow Democrats introduced legislation aimed at lowering medicine prices.

You Might Also Like
  • U.S. Senate Finance Committee Invites Pharma Execs to Testify
  • U.S. FDA Moves to Prevent Pharma from “Gaming” Generic Drug System
  • U.S. Senators Tell Drug Company Execs Pricing Is Morally Repugnant

Rep. Elijah Cummings (D-Md.), who chairs the U.S. House Oversight Committee, sent letters to 12 drug makers seeking information on price increases, investment in research and development, and corporate strategies to preserve market share and pricing power, his office said in a statement.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

AbbVie Inc., Amgen Inc., AstraZeneca PLC, Celgene Corp, Eli Lilly and Co., Johnson & Johnson, Mallinckrodt PLC, Novartis AG, Novo Nordisk, Pfizer Inc., Sanofi and Teva Pharmaceutical all received letters seeking information about their pricing practices.

Novo Nordisk, Amgen, Celgene and Novartis said they were reviewing the request. The other drug companies did not immediately respond to requests for comment.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Cummings’ letters focused on drugs that are the costliest to Medicare Part D, a program that helps beneficiaries of the federal health insurance program for the elderly and disabled pay for self-administered medicines like those purchased at drugstores, as well as drugs that have had the largest price increases over a five-year period.

They include AbbVie’s Humira, the world’s top-selling medicine that had a price increase at the start of the year, Johnson & Johnson’s blockbuster cancer drug Imbruvica and several diabetes medications.

President Donald Trump made high prescription drug prices a top issue in the 2016 U.S. presidential campaign and said that drug companies were “getting away with murder.” The U.S. Department of Health and Human Services (HHS) last year rolled out a plan to lower drug prices and has introduced several modest proposals to curb medicine costs, but Democrats have said President Trump and his administration are not doing enough.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Several pharmaceutical companies temporarily froze prices on select drugs last year after being criticized by President Trump on Twitter. But drug makers raised prices on more than 250 prescription drugs to begin 2019.

Cummings, along with Sen. Bernie Sanders (I-Vt.), an independent who caucuses with Democrats, introduced three bills last week aimed at lowering drug prices.

That legislation would peg U.S. prescription drug prices to the median price from five countries—Canada, Britain, France, Germany and Japan—where drug costs are typically far lower because of government price controls. It would also allow Americans to import medication from Canada and other countries, as well as allow the HHS secretary to negotiate prices in Medicare Part D.

Filed Under: Drug Updates Tagged With: costs, drug cost, drug cost legislation, U.S. Congressional Budget Office

You Might Also Like:
  • U.S. Senate Finance Committee Invites Pharma Execs to Testify
  • U.S. FDA Moves to Prevent Pharma from “Gaming” Generic Drug System
  • U.S. Senators Tell Drug Company Execs Pricing Is Morally Repugnant
  • Making Sense of Drug Pricing Legislation

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.